NASDAQ:EYEN Eyenovia (EYEN) Stock Price, News & Analysis $10.38 -0.50 (-4.60%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eyenovia Stock (NASDAQ:EYEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eyenovia alerts:Sign Up Key Stats Today's Range$9.73▼$14.3350-Day Range$1.04▼$10.8852-Week Range$0.85▼$124.80Volume3.94 million shsAverage Volume1.23 million shsMarket Capitalization$29.89 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingHold Company OverviewEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Read More… Eyenovia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreEYEN MarketRank™: Eyenovia scored higher than 20% of companies evaluated by MarketBeat, and ranked 872nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingEyenovia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageEyenovia has received no research coverage in the past 90 days.Read more about Eyenovia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eyenovia are expected to grow in the coming year, from ($41.60) to ($16.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyenovia is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyenovia is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Eyenovia's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.05% of the float of Eyenovia has been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eyenovia has recently decreased by 31.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEyenovia does not currently pay a dividend.Dividend GrowthEyenovia does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.05% of the float of Eyenovia has been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eyenovia has recently decreased by 31.49%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.65 News SentimentEyenovia has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Eyenovia this week, compared to 2 articles on an average week.Search Interest24 people have searched for EYEN on MarketBeat in the last 30 days. This is an increase of 243% compared to the previous 30 days.MarketBeat Follows1 people have added Eyenovia to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eyenovia insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of Eyenovia is held by insiders.Percentage Held by InstitutionsOnly 25.84% of the stock of Eyenovia is held by institutions.Read more about Eyenovia's insider trading history. Receive EYEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter. Email Address EYEN Stock News HeadlinesEyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain EngagementJune 30 at 5:55 PM | finance.yahoo.comEyenovia Announces Co-Branded Validator with KinetiqJune 25, 2025 | tmcnet.comTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President Trump's Executive Order #14196 could not only save Social Security from collapse... ...but potentially increase benefits by up to 400%, according to legendary investor Louis Navellier. | InvestorPlace (Ad)Eyenovia, Inc. Acquires $50 Million in HYPE Tokens, Plans Validator Deployment and FDA Registration for Optejet UFD - NasdaqJune 25, 2025 | nasdaq.comEyenovia Climbs After-Hours On Revealing $50M Crypto Play And Validator Node PlansJune 24, 2025 | msn.comEyenovia, Inc. Acquires $50 Million in HYPE Tokens, Plans Validator Deployment and FDA Registration for Optejet UFDJune 23, 2025 | quiverquant.comQChardan Expands into Digital Assets by Advising Strategic Crypto-Backed FinancingsJune 18, 2025 | prnewswire.comEyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital GroupJune 18, 2025 | globenewswire.comSee More Headlines EYEN Stock Analysis - Frequently Asked Questions How have EYEN shares performed this year? Eyenovia's stock was trading at $11.68 at the beginning of 2025. Since then, EYEN shares have decreased by 11.1% and is now trading at $10.38. View the best growth stocks for 2025 here. How were Eyenovia's earnings last quarter? Eyenovia, Inc. (NASDAQ:EYEN) issued its quarterly earnings results on Monday, May, 19th. The company reported ($1.59) EPS for the quarter, beating analysts' consensus estimates of ($7.20) by $5.61. The business earned $1.60 million during the quarter, compared to the consensus estimate of $1.60 million. Eyenovia had a negative trailing twelve-month return on equity of 1,108.24% and a negative net margin of 62,238.41%. When did Eyenovia's stock split? Eyenovia shares reverse split before market open on Monday, February 3rd 2025.The 1-80 reverse split was announced on Tuesday, January 28th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Eyenovia IPO? Eyenovia (EYEN) raised $30 million in an initial public offering on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. How do I buy shares of Eyenovia? Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eyenovia investors own include Plug Power (PLUG), Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Pfizer (PFE), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings5/19/2025Today6/30/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EYEN CIK1682639 Webwww.eyenoviabio.com Phone(917) 289-1117FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside-80.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($58.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.82 million Net Margins-62,238.41% Pretax Margin-62,238.41% Return on Equity-1,108.24% Return on Assets-316.90% Debt Debt-to-Equity Ratio0.58 Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual Sales$60 thousand Price / Sales486.24 Cash FlowN/A Price / Cash FlowN/A Book Value($695.52) per share Price / Book-0.01Miscellaneous Outstanding Shares2,880,000Free Float2,678,000Market Cap$29.17 million OptionableOptionable Beta0.99 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:EYEN) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyenovia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.